Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cynosure, Inc.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
- Other Names / Subsidiaries
- Palomar Medical Techologies